Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 429-439

  Darcy, Kathleen M ^a   Birrer, Michael J ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Markers; Novel therapies; Ovarian cancer; Profiles; Translational research; Tumor biology

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLIN E; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DASATINIB; DOXORUBICIN; ENZASTAURIN; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MOTESANIB; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY EVALUATION PROGRAM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; DNA REPAIR; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; EPITHELIAL OVARIAN CANCER; FALLOPIAN TUBE CANCER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GYNECOLOGIC ONCOLOGY GROUP; GYNECOLOGIC SURGERY; GYNECOLOGICAL EXAMINATION; HEALTH PROGRAM; HUMAN; IMMUNOHISTOCHEMISTRY; MAINTENANCE THERAPY; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIMARY PERITONEAL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE;

FEMALE; HUMANS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951938162     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.048     Document Type: Article

References (59)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV epithelial ovarian cancer. N Engl J Med 334 1 (1996) 1-6
2. Farley J., Smith L.M., Darcy K.M., Sobel E., O'Connor D., Henderson B., et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63 (2003) 1235-1241
3. Darcy K.M., Brady W.E., McBroom J.W., Bell J.G., Young R.C., McGuire W.P., et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage and suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 111 3 (2008) 487-495
4. Farley J., Fuchiuji S., Darcy K.M., Tian C., Hoskins W.J., McGuire W.P., et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 113 3 (2009) 341-347
5. Darcy K.M., Brady W.E., Blancato J.K., Dickson R.B., Hoskins W.J., McGuire W.P., et al. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 114 3 (2009) 472-479
6. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clarke-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 4 (2001) 1001-1007
7. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 18 1 (2000) 106-115
8. Havrilesky L., Darcy K.M., Hamdan H., Priore R.L., Leon J., Bell J., and Berchuck A. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 20 (2003) 3814-3825
9. Secord A.A., Lee P.S., Darcy K.M., Havrilesky L.J., Grace L.A., Marks J.R., and Berchuck A. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 101 3 (2006) 390-397
10. Secord A.A., Lee P.S., Jewell E., Havrilesky L., Grace L., Murphy Berchuck A., et al. The role of methylation in the regulation of angiogenic inhibitors in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 101 (2006) S84
11. Secord A.A., Darcy K.M., Hutson A., Lee P.S., Havrilesky L.J., Grace L.A., et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 106 1 (2007) 221-232
12. Rubatt J.M., Darcy K.M., Hutson A., Bean S., Havrilesky L.J., Grace L.A., et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol 112 3 (2009) 469-474
13. Havrilesky L., Alvarez A., Whitaker R., Marks J., and Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations: a Gynecologic Oncology Group study. Gynecol Oncol 80 2 (2001) 283
14. Havrilesky L.J., Fleming N.D., Miner Z., Darcy K., Hutson A., Berchuck A., et al. Correlations between cell cycle regulatory genes and relationship to ovarian cancer prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 104 (2007) S54
15. Jewell E.L., Darcy K.M., Hutson A., Lee P.S., Havrilesky L.J., Grace L.A., et al. Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously-untreated, advanced stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115 3 (2009) 424-429
16. Burger R.A., Darcy K.M., DiSaia P.J., Monk B.J., Grosen E.A., Gatanaga T., et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a Gynecologic Oncology Group study. Cancer 101 1 (2004) 106-115
17. Bell J., Brady M., Young R., Lage J., Walker J., Look K.Y., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102 3 (2006) 432-439
18. Farley J.H., Smith L., Darcy K.M., Tian C., Sobel E., and Birrer M.J. Alterations in cyclin E and p27 in early epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 84 3 (2002) 499
19. Garg R., Garcia R.L., Brady M.F., Goff B.A., and Paley P. Angiogenic marker alteration in high-risk stage I or II epithelial ovarian cancer. Gynecol Oncol 104 3 (2007) S43
20. Ozol R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson, Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 17 (2003) 3194-3200
21. Darcy K.M., Tian C., and Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67 9 (2007) 4474-4481
22. Pejovic T., Gaile D.P., Darcy K.M., Liu S., Shepherd L., Rodgers W.H., et al. A Gynecologic Oncology Group study of frequent copy number aberrations in DNA repair genes and other genomic regions in stage I serous ovarian cancers. J Clin Oncol 27 (2009) ASCO Abstract #e16504
23. Gaile D.P., Shepherd L., Liu S., Darcy K., Brady M., and Morrison C. iGenomic Viewer, a Gynecologic Oncology Group software library for the creation of highly customizable, portable, interactive, and linked visualizations of high throughput genomic data. J Clin Oncol 27 (2009) ASCO Abstract # e16544
24. Armstrong D.K., Bundy B.N., Wenzel L., Huang H.Q., Baergen R., Lele S.B., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (2006) 34-43
25. Bookman M., Brady M., McGuire W., Harper P., Alberts D., Friedlander M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27 9 (2009) 1419-1425
26. Gallion H., Kryscio R., Clarke-Pearson D., DiSaia P., Fowler J., Mannel R., et al. The prognostic significance of germline BRCA1 mutations in epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 88 2 (2003) 157
27. Wilcox C.B., Baysal B.E., Gallion H.H., Strange M.A., and DeLoia J. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159 2 (2005) 114-122
28. Thrall M., Gallion H.H., Kryscio R., Kapali M., Armstrong D.K., and Deloia J.A. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 16 Suppl. 1 (2006) 166-171
29. Baysal B.E., DeLoia J.A., Willett-Brozick J.E., Goodman M.T., Brady M.F., Modugno F., et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 95 1 (2004) 62-69
30. Krivak T.C., Darcy K.M., Tian C., Armstrong D., Baysal B.E., Gallion H., et al. Relationship between ERCC1 polymorphisms and disease progression and survival in the Gynecologic Oncology Group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26 21 (2008) 3598-3606
31. Krivak T.C., Darcy K., Tian C., Bookman M.A., Baysal B.A., Gallion H., et al. Relationship between ERCC1 polymorphism, disease progression and survival in GOG0182: a Gynecologic Oncology Group phase III trial of platinum-based chemotherapy in women with advanced stage epithelial ovarian or primary peritoneal cancer. J Clin Oncol 26 15s (2008) 302s
32. Krivak T.C., Tian C., DeLoia J.A., Darcy K.M., Armstrong D., Gallion H., et al. BRCA1/BRCA2 polymorphisms and prognosis in women with optimally-resected stage III epithelial ovarian cancer treated on GOG Protocol 172: a Gynecologic Oncology Group study. Gynecol Oncol 112 2 (2009) S9
33. Darcy K.M., Tian C., Ambrosone C.B., Krivak T.C., Armstrong D., Bookman M.A., et al. A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2 and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy. J Clin Oncol 27 15S (2009) s293
34. Garcia A.A., Blessing J.A., Lenz H.J., Darcy K.M., Mannel R.S., Miller D.S., et al. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 96 3 (2005) 810-811
35. Aghajanian C., Blessing J.A., Darcy K.M., Reid G., DeGeest K., Rubin S.C., et al. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115 2 (2009) 215-220
36. Secord A.A., Blessing J.A., Armstrong D.K., Rodgers W.H., Miner Z., Barnes M.N., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian or cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 108 3 (2008) 493-499
37. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody (Trastuzumab) in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol 21 2 (2003) 283-290
38. Schilder R., Sill M., Chen X., Darcy K., DeCesare S., Lewandowski G., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res. 11 15 (2005) 5539-5548
39. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 33 (2007) 5165-5171
40. Han E.S., Burger R., Darcy K.M., Sill M., Greer B.E., Sorosky J..I., and Fruehauf J.P. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). J Clin Oncol 26 15S (2008)
41. Schilder R.J., Sill M.W., Lee R.B., Shaw T.J., Senterman M.K., Klein-Szanto A.J.P., et al. Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 26 20 (2008) 3418-3425
42. Zorn K.K., Jazaeri A.A., Awtrey C.S., Gardner G.J., Mok S.C., Goyd J., et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 9 13 (2003) 4811-4818
43. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression of serous, endometrioid, and clear cell types of ovarian and endometrial cancer. Clin Cancer Res 11 18 (2005) 6422-6430
44. Mo Y.Y., Yu Y., Theodosiou E., Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 24 16 (2007) 2677-2683
45. He X., Ee P.L., Coon J., and Beck W.T. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10 4 (2004) 4652-4660
46. He X., Pool M., Darcy K.M., Lim S.B., Auersperg N., Coon J.S., et al. Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene 26 34 (2007) 4961-4968
47. Smith S.A., Richards W.E., Caito K., Hanjani P., Markman M., Degeest K., et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol 83 3 (2001) 586-592
48. Reedy M., Gallion H., Fowler J., Kryscio R., and Smith S. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 85 2 (2002) 255-259
49. Greene M.H., Piedmonte M., Alberts D., Gail M., Hensley M., Miner Z., et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17 3 (2008) 594.604
50. Antoniou A.C., Sinilnikova O., McGuffog L., Healey S., Nevanlinna H., Simard J., et al. Common variants in 8q24, LSP1 and 2q35 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18 22 (2009) 4442-4456
51. Darcy K.M., Wohlhueter A.L., Zangani D., Vaughan M.M., Russell J.A., Masso-Welch P.A., et al. Selective changes in EGF receptor expression and function during the proliferation, functional differentiation and apoptosis of mammary epithelial cells. Euro J Cell Biol 78 (1999) 511-523
52. Darcy K.M., Zangani D., Wohlhueter A.L., Huang R.-Y., Vaughan M.M., Russell J.A., et al. Changes in ErbB2 (HER-2/neu), ErbB3 and ErbB4 during the growth, differentiation and apoptosis of normal rat mammary epithelial cells. J Histochem Cytochem 48 1 (2000) 63-80
53. http://www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slides-and/signaling-pathways.html.
54. http://www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slides-and/regulatory-cascade-of-cyclin-gene-expression.html.
55. http://www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slides-and/g1-and-s-phases-of-the-cell-cycle.html.
56. Vilmar A., and Sørensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64 2 (2009) 131-139
57. Durant S.T., and Nickoloff J.A. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle 4 9 (2005) 1216-1222
58. Weberpals J.I., Clark-Knowles K.V., and Vanderhyden B.C. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 26 19 (2008) 3259-3267
59. Bolderson E., Richard D.J., Zhou B.-B.S., and Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand repair. Clin Cancer Res 15 20 (2009) 6314-6320